Brain death determination is one of the most consequential clinical decisions made in the intensive care unit. It demands absolute certainty, rigorous protocol adherence, and — when clinical examination alone falls short — reliable ancillary testing. For clinic directors and healthcare decision-makers evaluating diagnostic technologies for their neurocritical care programs, Transcranial Doppler (TCD) ultrasonography has emerged as a powerful, evidence-based tool for confirming cerebral circulatory arrest (CCA) in brain death evaluation.

This article explores the clinical rationale, diagnostic accuracy, examination protocol, and practical advantages of incorporating TCD into your facility’s brain death determination workflow — and why automated TCD platforms like the NG2 Intelligent Ultrasound are making this capability more accessible than ever.

Understanding Brain Death and the Need for Ancillary Testing

Brain death is defined as the irreversible cessation of all brain function, including the brainstem. In the United States, the 2023 AAN/AAP/CNS/SCCM consensus guideline provides the most current framework for brain death and death by neurologic criteria (BD/DNC) determination. The guideline outlines a structured clinical examination — including assessments of consciousness, brainstem reflexes, and the apnea test — as the primary pathway to diagnosis.

However, the guideline also recognizes that clinical assessment cannot always be completed. Confounding factors such as residual sedative or barbiturate levels, therapeutic hypothermia, hemodynamic instability, severe facial or cranial trauma, and marked metabolic derangements can prevent clinicians from performing or interpreting the full clinical exam with confidence. In these scenarios, ancillary testing becomes not just helpful but required.

This is precisely where TCD proves its value. Unlike electroencephalography (EEG), which measures neuronal electrical activity and is highly susceptible to interference from CNS depressants, TCD evaluates cerebral blood flow — a fundamentally different physiologic parameter. This distinction makes TCD especially useful in patients receiving barbiturate therapy or other sedation protocols where EEG findings would be unreliable.

How TCD Detects Cerebral Circulatory Arrest

Transcranial Doppler ultrasonography confirms brain death by detecting the cessation of blood flow to the brain. As intracranial pressure (ICP) rises — a hallmark of the pathophysiology leading to brain death — it progressively overcomes cerebral perfusion pressure, ultimately halting forward blood flow through the cerebral vasculature. TCD captures this process through a characteristic and well-documented progression of waveform changes:

Increasing pulsatility — The pulsatility index rises as ICP increases, with diastolic flow still present. This stage indicates worsening hemodynamics but does not yet confirm CCA.
Oscillating (reverberating) flow — Forward systolic flow is followed by reversed diastolic flow, producing a distinctive to-and-fro pattern. This occurs when ICP equals mean arterial pressure, resulting in zero net forward perfusion.
Systolic spikes — Small, brief systolic deflections appear with no diastolic component, indicating that ICP is approaching systolic blood pressure.
Absent signal — Complete disappearance of any Doppler signal, representing the final stage of circulatory arrest.

The World Federation of Neurology (WFN) Task Force consensus has established that oscillating flow and systolic spikes are the definitive Doppler patterns confirming CCA. These findings, when identified across the required vessels, provide high-confidence confirmation of brain death.

Diagnostic Accuracy: What the Evidence Shows

For clinic directors weighing the addition of TCD to their diagnostic toolkit, the evidence base is compelling. A systematic review and meta-analysis published in the American Journal of Neuroradiology (Chang et al., 2016) evaluated the diagnostic accuracy of TCD for brain death confirmation and found high sensitivity and specificity across multiple studies. A separate meta-analysis by Monteiro et al. in Intensive Care Medicine (2006) corroborated these findings, establishing TCD as a reliable ancillary test with strong positive and negative predictive values. Importantly, a retrospective analysis by Sharma et al. published in Neurocritical Care (2011) examined 90 patients in whom clinical brain death diagnosis was not feasible due to confounding factors. TCD confirmed brain death in 57% of these cases. Among patients who showed CCA patterns in at least one artery but did not meet full bilateral criteria, 74% were subsequently confirmed brain dead or experienced cardiovascular death — suggesting that TCD also carries significant prognostic value even in incomplete examinations. These findings underscore that TCD is not merely a supplementary test but a clinically meaningful tool that can drive timely and accurate decision-making in the most complex ICU scenarios.

The TCD Examination Protocol for CCA

Based on international consensus guidelines and society recommendations, the standardized TCD protocol for evaluating cerebral circulatory arrest includes the following key elements:

Vessels insonated: Both middle cerebral arteries (MCAs) and the basilar artery must be examined. CCA patterns must be confirmed in all three vessels to meet diagnostic criteria.
Equipment: A 2 MHz pulsed-wave Doppler probe with a sample volume of less than 10 mm is used, applied through the temporal and suboccipital acoustic windows.
Confirmation: The examination must be repeated within 30 minutes to confirm that CCA patterns persist, ruling out transient hemodynamic fluctuations.
Patient prerequisites: The patient must be hemodynamically stable (systolic blood pressure >90–100 mmHg), normothermic (>32°C), normocapnic, and free of severe metabolic derangements that could independently affect cerebral blood flow.

This protocol, outlined by the WFN Task Force (Ducrocq et al., 1998) and further refined by Segura et al. (2009), ensures standardized, reproducible, and defensible results — a critical consideration for any facility establishing or refining its brain death determination policy.

When TCD Is Especially Valuable in the ICU

While TCD can be used as an ancillary test in any brain death evaluation, its advantages are most pronounced in specific clinical scenarios that frequently arise in neurocritical care:

Sedative and barbiturate therapy: Patients receiving therapeutic barbiturate coma for refractory intracranial hypertension present a significant diagnostic challenge. EEG is unreliable in this setting because barbiturates suppress cortical electrical activity. TCD, which measures blood flow rather than neuronal function, remains diagnostically valid.
Therapeutic hypothermia: Targeted temperature management protocols can confound the clinical neurological examination, making ancillary confirmation essential.
Hemodynamic instability: When a patient cannot tolerate the apnea test due to cardiovascular instability, TCD provides an alternative pathway to confirm CCA without the physiologic stress of prolonged apnea.
Severe craniofacial trauma: Extensive facial or orbital injuries may preclude assessment of certain brainstem reflexes, necessitating ancillary confirmation.
Organ donation timelines: In cases where organ procurement is being considered, TCD can expedite the confirmation process, supporting optimal organ viability and transplant outcomes. Timely brain death determination directly impacts the quality and availability of donor organs — a consideration with profound implications for transplant programs and the patients they serve.

Why Automated TCD Changes the Equation for Your Facility

Traditional TCD has long been recognized for its clinical utility, but its adoption has been limited by a practical barrier: operator dependency. Conventional handheld TCD requires a skilled vascular sonographer to locate the temporal acoustic window, optimize the Doppler signal, and interpret waveforms in real time. Many facilities — particularly community hospitals and smaller neurocritical care units — lack 24/7 access to this specialized expertise.

This is where automated, robotic TCD technology fundamentally changes the calculus. The NeuraSignal NG2 Intelligent Ultrasound uses robotics and machine learning to autonomously identify the temporal window and optimize cerebral blood flow signals — tasks that previously required years of specialized training. This means that TCD examinations, including CCA assessments, can be performed by a broader range of healthcare providers at any hour, without waiting for a specialized sonographer.

For clinic directors evaluating TCD platforms, this translates to tangible operational benefits: expanded diagnostic capability, reduced dependency on scarce specialized personnel, faster time to diagnosis, and the ability to offer 24/7 ancillary testing for brain death determination. The NG2’s advanced algorithms provide insight into subtle hemodynamic changes, while NG View enables secure, cloud-based remote access to exam data — allowing neurointensivists to review TCD findings from anywhere and coordinate care across distributed clinical teams.

Beyond brain death assessment, adding TCD capability opens the door to a full spectrum of clinical applications — from vasospasm monitoring after subarachnoid hemorrhage to PFO detection, perioperative emboli monitoring, and post-thrombectomy surveillance. The investment in TCD infrastructure serves multiple clinical programs simultaneously, maximizing return on investment.

The Broader Impact: Supporting Your Neurocritical Care Program

For healthcare decision-makers, the case for TCD in brain death determination extends beyond the individual patient encounter. Facilities seeking or maintaining Comprehensive Stroke Center certification are already expected to have TCD capability. Incorporating automated TCD strengthens your program’s diagnostic portfolio, supports compliance with the latest clinical trial evidence and guideline recommendations, and positions your institution as a leader in evidence-based neurocritical care.

The peer-reviewed literature — including the foundational work by Llompart-Pou et al. (2013), the WFN consensus (Ducrocq et al., 1998), and the AAN practice parameters (Wijdicks et al., 2010) — consistently supports TCD as a high-accuracy, low-risk ancillary test. When combined with the operational advantages of robotic automation, the value proposition for clinic directors becomes clear.

Take the Next Step with NeuraSignal

Brain death determination demands the highest standards of clinical accuracy, and TCD has proven itself as a trusted, evidence-based tool for confirming cerebral circulatory arrest. With automated platforms like the NG2 Intelligent Ultrasound, this capability is now more accessible, more reliable, and easier to integrate into your existing ICU workflow than ever before.

If you’re ready to explore how TCD can enhance your facility’s neurocritical care capabilities, reach out to NeuraSignal to schedule a live demo. Our team will walk you through the technology, discuss implementation for your specific clinical environment, and show you firsthand how the NeuraSignal Platform supports faster, more confident brain death determination — and so much more.